fda mass compounding curbs

US FDA proposes curbs on mass compounding of Novo, Lilly's weight-loss drugs — Photo by 易凡 on Pexels

FDA Mass Compounding Curbs Reviewed: Safe Prescription Weight Loss?

The FDA estimates a 12% adverse event rate in GLP-1 weight-loss drugs, and its new curbs aim to improve safety by requiring finished-product sourcing rather than bulk compounding. By removing semaglutide, liraglutide and tirzepatide from the 503B bulk list, the agency hopes to standardize formulations and protect patients. Medical Disclaimer: